Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies

Hongliang Yu1, Li Yin1, Xuesong Jiang1, Xiujin Sun1, Jing Wu1, Hao Tian1, Xianshu Gao2, Xia He1*

1. Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P. R. China, 2. Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, P. R. China

*hexia200302@tom.com

Abstract

Background: Laboratory studies have shown the anti-tumor effect of metformin on prostate cancer. However, recent epidemiological studies have yielded inconclusive results.

Methods: We searched PubMed database from the inception to May 30 2014 for studies which assessed the effect of metformin use on cancer risk of prostate cancer, biochemical recurrence (BCR) and all-cause mortality of patients with prostate cancer. The pooled results and 95% confidence intervals (CIs) were estimated by random-effect model.

Results: Twenty-one studies were eligible according to the inclusion criteria. Based on the pooled results of available observational studies, metformin use was significantly associated with a decreased cancer risk (14 datasets, 963991 male subjects, odds ratio: 0.91, 95% CI: 0.85–0.97) and BCR (6 datasets, 2953 patients, hazard ratio: 0.81, 95% CI: 0.68–0.98) of prostate cancer. However, the association of metformin use with all-cause mortality of patients with prostate cancer was not significant (5 datasets, 9241 patients, hazard ratio: 0.86, 95% CI: 0.64–1.14).

Conclusion: Results suggest that metformin use appears to be associated with a significant reduction in the cancer risk and BCR of prostate cancer, but not in all-cause mortality of patients with prostate cancer.
Introduction
Prostate cancer is the most common male malignancy in the Western world, and the incidence in Asian countries has been increasing significantly in past decades [1]; therefore, methods for preventing and curing this malignancy are urgently needed.

Metformin is the most widely used oral hypoglycemic agent in type 2 diabetes, and it has a favorable toxicity profile and extremely low cost. Its primary action is the inhibition of hepatic glucose production through an LKB1/AMPK–mediated mechanism, and it also improves insulin sensitivity in peripheral tissues [2]. Recently, metformin has gained increasing interest in the medical community for its potential antitumorigenic effects [3]. Epidemiological studies have demonstrated that metformin can reduce the risk of breast, colon, pancreatic, and liver cancers and might even improve cancer prognosis [4]. Preclinical studies also have shown the beneficial effects of metformin on prostate cancer cells, as it can inhibit cell proliferation and induce the apoptosis of prostate cancer cell lines in vitro and in vivo [5]. However, epidemiologic studies have yielded inconsistent results; some of these works have shown that metformin indeed decreased the cancer incidence and promoted an improved cancer prognosis [6–10], while other studies found no such associations [11–13]. With these premises, we performed a systematic review and meta-analysis of the currently available studies to comprehensively explore the effects of metformin on both cancer prevention and the treatment outcomes of prostate cancer, specifically, its preventative qualities in regard to cancer risk and on its BCR as well as the all-cause mortality for the treatment outcomes of prostate cancer.

Methods
Data sources and research
Relevant studies were identified by searching the PubMed database (www.ncbi.nlm.nih.gov/pubmed), within the time frame from its inception to May 30, 2014. We limited the searches to studies in humans and published in English-language journals. We used relevant text words and medical subject headings that included “hypoglycemic agents” or “metformin” or “biguanides” in combination with “prostate” or “prostatic” and “cancer” or “neoplasm” or “carcinoma”. The reference lists of the identified articles were manually scanned to identify any other relevant studies. The ClinicalTrials.gov website was also searched for randomized trials that were registered as completed but not yet published. In addition, the references for the reviews and meta-analyses covered on this issue were also scrutinized to identify additional relevant publications [14–16].

Inclusion and exclusion criteria
The inclusion and exclusion criteria for this meta-analysis were as follows: the work (1) should be a published observational study or randomized clinical trial
evaluating the impact of exposure to metformin compared with a comparison group on the cancer risk and/or treatment outcomes of prostate cancer; (2) must have reported relative risks (RR), hazards ratios (HR) or odds ratios (OR) and 95% confidence intervals to estimate the effect of metformin on the cancer risk or treatment outcomes (BCR or all-cause mortality) of patients with prostate cancer; (3) must have clear information on the adjustments for confounding factors; and (4) must be an independent study to avoid assigning a double weight to estimates derived from the same study published twice or more.

Data extraction and study quality assessment
The results of the search strategy and the identified eligible studies were reviewed by two authors (Hongliang Yu and Xiujin Sun) independently. For each eligible study, we extracted the data using a standardized data-collection form, including details on the authors, study country, publication year, study design, study period, total number of male subjects and the number of cases of prostate cancer, comparison groups, effect estimates, adjustments or stratification variables and study quality. Discrepancies in the data extraction between the two reviewers were resolved by discussion.

The study quality was assessed by applying a 9-star system on the basis of the Newcastle-Ottawa Scale (NOS) [17], and a study with ≥7 awarded stars was defined as a high-quality study.

Statistical analysis
We pooled the effect estimates from the individual studies using a random effects model, which considered both within- and between-study variations, yielding more conservative results than the fixed-effect model [18]. For the cancer risk analysis, the OR was used as the common measure of association across studies, and the RR and HR were directly considered as the OR for the cancer incidence was relatively low [19]. For the BCR and all-cause mortality analysis, the HR was used as the common measure. Heterogeneity was evaluated using the I² test, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than to chance [20]. We also conducted subgroup analyses according to the study location, study design, comparison group and study population to assess the potential modification effects of these variables on the risk of prostate cancer. Additionally, a sensitivity analysis to investigate the influence of a single study on the overall risk estimate by omitting one study in turn was performed for all of the analyses. The potential publication bias was assessed by Begg’s funnel plots and Egger’s regression test [21]. A p value <0.05 was considered to be statistically significant, except where otherwise specified. All statistical analyses were performed with STATA version 12.0 (StataCorp).
Results

Literature search
We initially identified 135 potentially eligible studies by title and abstract screening, but most of them were excluded because the exposure or endpoint was not relevant to our analysis or they were fundamentally biochemical experimental research. After assessing the fulltext of the 29 potentially relevant studies, we identified 21 eligible studies [6–13, 22–34] for analyses. The primary reasons for exclusion were as follows: 5 studies did not specify the association between metformin and the cancer risk or treatment outcome of prostate cancer; the other 2 studies [35, 36] were duplicate reports of one included study [11] on the same populations; 1 study [37] was reported to be a prospective randomized trial design, but its initial intent was not to explore the relationship between metformin use and the risk of prostate cancer; it also did not clearly state the adjustments for confounding factors. As a result, all of the studies included in this study were retrospective in design. A flow chart showing the study selection process is presented in Fig. 1.

Study characteristics
The characteristics of the included studies are presented in Tables 1, 2, and 3. Of the included studies, nearly all of them were conducted in Western countries, 15 in North America and 6 in Europe; only 2 of the studies were conducted in East Asia in Taiwan. Of the 12 observational studies conducted to explore the association between metformin use and the risk of prostate cancer, 7 were retrospective cohort in design and 5 were case-control in design. The total number of all of the included male subjects in the cancer risk analysis was 963991. For the analyses of the effect of metformin on BCR and the all-cause mortality of prostate cancer, all of the studies were retrospective cohorts in design, and the total number of prostate cancer cases included was 2953 and 9241, respectively. We also observed that all of the studies were conducted between 2008 and 2014, which appears to reflect the currently rising interest of the medical community in the potential benefits of metformin use for prostate cancer.

The quality score of the included studies ranged from five to nine stars on the scale, and the median score of the included studies for the cancer risk, BCR and all-cause mortality analysis was 6, 8 and 8, respectively. The prevalence of a study quality lower than 7 in the cancer risk analysis may be because many of the included studies were not conducted not directly focused on exploring the association between metformin use and the risk of prostate cancer [7, 23, 24, 26, 32].

Primary analysis
The primary results of the meta-analysis are presented in Fig. 2. A forest plot graph of the association between metformin use and the risk of prostate cancer is shown in Fig. 2A, while Fig. 2B and 2C show the effect of metformin use on the
BCR and all-cause mortality of patients with prostate cancer after treatment, respectively.

As shown in Fig. 2A, metformin use showed a statistically significant beneficial effect on the risk of prostate cancer, with a summary OR of 0.91 (95% CI: 0.85–0.97). Moderate heterogeneity was found across the studies ($I^2 = 51\%$, $p = 0.01$).

The adjusted HR of each study and the summary HR for the effects of metformin use on the BCR of prostate cancer are shown in Fig. 2B. The summary HR was 0.81 (95% CI: 0.68–0.98), which demonstrated a statistically significant beneficial effect of metformin use on the BCR of prostate cancer. Little evidence of heterogeneity was found across the studies ($I^2 = 14\%$, $p = 0.33$).

We also studied the effect of metformin use on the all-cause mortality, which is a representative of the overall survival of patients with prostate cancer. As shown in Fig. 2C, in the included individual study showing converse results, the analysis failed to show a significant beneficial effect of metformin on the all-cause mortality of prostate cancer, with a summary HR of 0.86 (95% CI: 0.64–1.14). Heterogeneity was found to be statistically significant across the studies ($I^2 = 78\%$, $p < 0.01$).

Subgroup and sensitivity analyses
To explore the potential source of the heterogeneity across studies, we performed a subgroup study. Because there were differences in the study locations, study design and comparison groups within the included studies that could markedly modify the results of the included studies, we investigated the influence of these subgroups. The subgroup study for the cancer risk analysis is shown in Table 4. The subgroup study showed that little evidence of between-subgroup hetero-
Heterogeneity was observed in the studies subgrouped by study location and study design, whereas significant between-subgroup heterogeneity was observed between the studies subgrouped by the comparison group design ($I^2=92\%$, $p<0.01$). Because of the limited number of included studies for the BCR and all-cause mortality analyses, subgroup studies were not performed for these two analyses.

Sensitivity analyses were conducted to verify the effect of each study on the overall estimate by omitting one study at a time and calculating the combined results for the remaining studies. The sensitivity analyses are shown in S1 Fig. The results of the sensitivity study for the cancer risk analysis showed good
### Table 2. Characteristics of the included studies for the BCR of prostate cancer analysis.

| Author publication year | Country/region | Study design | Study period(years) | PCa cases | Patients undergo BCR | Treatment comparison | Measure of outcome | Adjustments* | Study quality score |
|-------------------------|----------------|-------------|---------------------|-----------|---------------------|----------------------|-------------------|--------------|-------------------|
| Allott et al.,2013      | USA            | retrospective cohort study | 22(1988–2010) | 371       | 134 prostatectomy+metformin vs prostatectomy without metformin | aHR                   | 1,6,7,13,18,19,21,23,24 | 8            |
| Kaushik et al.,2013     | USA            | retrospective cohort study | 13(1997–2010) | 885       | 203 prostatectomy+metformin vs prostatectomy without metformin use | aHR                   | 1,6,7,16,18,19,21 | 8            |
| Patel et al.,2010       | USA            | retrospective cohort study | 19(1990–2009) | 210       | 79 prostatectomy+metformin vs prostatectomy without metformin use | aHR                   | 1,7,18,21,22    | 8            |
| Rieken et al.,2013      | USA and Europe | retrospective cohort study | 11(2000–2011) | 664       | 173 prostatectomy+metformin vs prostatectomy without metformin use | aHR                   | 1,7,19,21–23,24 | 7            |
| Spratt et al.,2013      | USA            | retrospective cohort study | 16(1992–2008) | 319       | 79 radiotherapy+metformin vs radiotherapy without metformin | aHR                   | 1,7,17–19      | 8            |
| Zannella et al.,2013    | Canada         | retrospective cohort study | 16(1996–2012) | 504       | 165 radiotherapy+metformin vs radiotherapy without metformin | aHR                   | 1,7,16–19      | 7            |

* Adjustments: 1.Age, 2.smoking status, 3.prior cancer diagnosis, 4.place of residency, 5.use of other diabetes medications, 6.BMI, 7.PSA value, 8.family history of prostate cancer, 9.HbA1c, 10.Comorbidities, 11.Townsend index of deprivation, 12.excessive alcohol use, 13.race/ethnicity, 14.year of diagnosis, 15.socioeconomic status, 16.other drug use, 17.ADT treatment, 18.T stage, 19.Gleason score, 20.primary treatment with radiation or surgery, 21.surgical margin, 22.lymph node metastasis, 23. extracapsular extension, 24. seminal vesicle invasion.

doi:10.1371/journal.pone.0116327.t002

### Table 3. Characteristics of the included studies for the all-cause mortality of the prostate cancer analysis.

| Author publication year | Country/region | Study design | Study period(years) | PCa cases | Patients death | Treatment comparison | Measure of outcome | Adjustments* | Study quality score |
|-------------------------|----------------|-------------|---------------------|-----------|----------------|----------------------|-------------------|--------------|-------------------|
| Spratt et al.,2013      | USA            | retrospective cohort study | 16(1992–2008) | 2901      | 199 radiotherapy+metformin vs radiotherapy without metformin | aHR                   | 1,7,17–19      | 8            |
| He et al.,2011          | USA            | retrospective cohort study | 9(1999–2008) | 233       | / ever vs never use of metformin | aHR                   | 1,6,13,18,19    | 8            |
| Margel et al.,2013      | Canada         | retrospective cohort study | 12(1997–2009) | 3837      | 1343 ever vs never use of metformin | aHR                   | 1,10,14–18,20  | 9            |
| Kaushik et al.,2013     | USA            | retrospective cohort study | 13(1997–2010) | 885       | 94 prostatectomy+metformin vs prostatectomy without metformin | aHR                   | 1,6,7,16,18,19,21 | 8            |
| Currie et al.,2012      | UK             | retrospective cohort study | 19(1990–2009) | 1385      | 465 ever vs never use of metformin | aHR                   | 1,2,10,11,14   | 8            |

* Adjustments: 1.Age, 2.smoking status, 3.prior cancer diagnosis, 4.place of residency, 5.use of other diabetes medications, 6.BMI, 7.PSA value, 8.family history of prostate cancer, 9.HbA1c, 10.Comorbidities, 11.Townsend index of deprivation, 12.excessive alcohol use, 13.race/ethnicity, 14.year of diagnosis, 15.socioeconomic status, 16.other drug use, 17.ADT treatment, 18.T stage, 19.Gleason score, 20.primary treatment with radiation or surgery, 21.surgical margin, 22.lymph node metastasis, 23. extracapsular extension, 24. seminal vesicle invasion.

doi:10.1371/journal.pone.0116327.t003
consistency, and omitting any one of the included studies did not significantly affect the combined estimate, with a fairly narrow range of results, from 0.89 (95% CI: 0.84–0.95) to 0.93 (95% CI: 0.87–0.99), indicating that the pooled estimate of our analysis was statistically robust. The sensitivity study for the BCR analysis showed that the study by Spratt et al. \cite{10} affected the summary estimate foremost, and omitting this study yielded a result of 0.88 (95% CI: 0.73–1.05), whereas omitting the remaining studies one at a time yielded fairly consistent results, ranging from 0.78 (95% CI: 0.63–0.98) to 0.83 (95% CI: 0.68–1.01). The sensitivity study for the all-cause mortality analysis showed a poor consistency of the results, with a wide range, from 0.75 (95% CI: 0.51–1.10) to 0.98 (95% CI: 0.77–1.26).

**Publication bias**

The Begg’s funnel plots for the three meta-analyses did not demonstrate any substantial asymmetry, which was shown in S2 Fig. Egger’s regression test also indicated little evidence of publication bias, with p value of 0.85, 0.45 and 0.74, respectively, for the cancer risk, BCR and all-cause mortality analyses.

**Discussion**

Metformin has recently garnered increasing interest from the medical community for its potential beneficial effects on prostate cancer. Much of the work dedicated to this issue has been performed in the past 5 years and has yielded inconsistent results. This study is the first comprehensive meta-analysis and systematic review of the available studies focused on the effects of metformin both on the prevention and treatment of prostate cancer.

The combined 12 epidemiologic studies and 14 datasets showed that metformin use lowered the cancer risk by 9%, with a summary OR of 0.91 (95% CI: 0.85–0.97, \( p < 0.01 \)). The BCR can indicate disease progression years before clinical signs or symptoms develop and most likely implies the failure of prostate cancer treatment \cite{38}. Therefore, the association between metformin use and the BCR of prostate cancer was also studied in this study. The meta-analysis of the 6 available retrospective cohort studies showed that metformin use significantly reduced the risk of a BCR of prostate cancer after treatments, with a summary HR of 0.81 (95% CI: 0.68–0.98, \( p = 0.03 \)). Several mechanisms may be involved in the beneficial effect of metformin for prostate cancer. Studies have revealed that metformin may activate the LKB1/AMPK signal pathway, inhibit protein
synthesis, and induce cell cycle arrest and/or cell apoptosis, as well as eradicate cancer stem cells [3], thereby potentially reducing the cancer risk and BCR after the treatment of prostate cancer.

Prostate cancer is a disease with a slow progression, and patients may die with this disease but not of this disease [38]. Metformin can affect the metabolism and inner environment of the human body in multiple ways. How metformin affects the all-cause mortality of prostate cancer is also a concern of this study. Due to the limited number of available studies and the markedly converse study results, the summary result of 5 retrospective cohort studies failed to show a significant beneficial effect for metformin on the all-cause mortality of prostate cancer, with a summary HR of 0.86 (95% CI: 0.64–1.14, \( p = 0.29 \)).

Heterogeneity is often a concern of a meta-analysis. We found a moderate heterogeneity (\( I^2 = 51\% \), \( p = 0.01 \)) existing in the analysis of the association of metformin use and the cancer risk of prostate cancer. To investigate the validity of our result and the source of the heterogeneity, we performed sensitivity and subgroup studies. The sensitivity study yielded consistent results; the ORs after omitting one study at a time were all statistically significant and similar to one another, indicating that our results were statistically robust. The subgroup study showed that the differences in the comparison group design and details such as metformin vs. other hypoglycemic agents in patients with diabetes or users vs. nonusers of metformin in the general population significantly contribute to the overall heterogeneity. The potential rationale for this may be the difference between the nature of the two comparator groups. As non-user of metformin group involves both patients with other hypoglycemic agents and population without any diabetic drugs. Besides, some diabetic medications other than metformin may also affect the incidence of prostate cancer [6, 23].

### Table 4. Subgroup analysis of the effect of metformin use on the cancer risk of prostate cancer.

| Group                    | No. of data sets | OR(95% CI) | Heterogeneity within subgroups | Heterogeneity between subgroups |
|--------------------------|------------------|------------|-------------------------------|--------------------------------|
| Total                    | 13               | 0.92(0.85–0.99) | 52% 0.02                      |                                  |
| Study location           |                  |            |                                |                                  |
| North America            | 6                | 0.95(0.84–1.08) | 60% 0.05                      |                                  |
| Europe                   | 5                | 0.87(0.80–0.94) | 51% 0.08                      |                                  |
| East Asia                | 3                | 0.87(0.66–1.13) | 0 0.69                        |                                  |
| Study design             |                  |            |                                |                                  |
| Retrospective cohort study | 9             | 0.93(0.89–0.96) | 0 0.64                        |                                  |
| Case-control study       | 5                | 0.91(0.75–1.11) | 78% <0.01                     |                                  |
| Comparison group         |                  |            |                                |                                  |
| Metformin vs other hypoglycemic agents | 10 | 0.95(0.90–1.01) | 22% 0.24                      |                                  |
| Metformin user vs nonuser | 4              | 0.81(0.75–0.87) | 0 0.56                        |                                  |

doi:10.1371/journal.pone.0116327.t004
prostate cancer could still not be ruled out as a cofounding fact. Nevertheless, our findings support Preston’s study [34], metformin users had a more pronounced reduction in cancer risk compared with users of other diabetic medications or no diabetic medications. In our study, substantial heterogeneity was also found in the all-cause mortality analysis. Many reasons may contribute to it. Firstly, only a few studies were available for evaluating the association of metformin use and all-cause mortality of patients with prostate cancer. The study design in these studies were with obvious differences. For example, the study by Kaushik et al [13] investigated patients with prostate cancer treated with surgery, while patients in the study by Spratt et al [10] were treated with radiotherapy. In the study by Margel et al [25], they used cumulative use of metformin as the exposure and evaluated the dose-response effect of metformin on the results, yielded significant benefit effect of metformin use on the all-cause mortality. While Currie et al [29] defined exposure as ever exposed to metformin immediately before and after cancer diagnosis, yielded an opposite result. Secondly, all-cause mortality may be influenced by many facets of facts, such as characteristics of study population, the stage and treatments of cancer, and the comorbidity of the included patients. All these may induce heterogeneity in the all-cause mortality analysis. For the meta-analysis of the association between metformin use and the BCR after treatment of prostate cancer, little evidence of heterogeneity was found ($I^2=14\%$, $p=0.33$). Because of the limited number of available studies for the BCR and all-cause mortality analyses, a subgroup study was not performed for these two analyses.

Several previous studies have evaluated the effect of metformin use on the risk of cancers in patients with type 2 diabetes [14–16, 39]. However, this study is the first study which specifically focused on exploring the association between metformin and the risk of prostate cancer. Moreover, our study identified 12 studies with 14 data sets and included 963991 male subjects, a much larger population than any existing analysis [15, 16]. As a consequence, our results gained much stronger statistical power. Additionally, our results are consistent with previous studies suggesting a protective role of metformin for the prevention of prostate cancer [15]. Nevertheless, we still suggest that further studies should be undertaken to confirm or refute the results of our analyses.

In addition to the cancer risk, this study also studied the association between metformin use and treatment outcomes, which includes the BCR and all-cause mortality of prostate cancer. To the best of our knowledge, it is the first study focused on this issue, which may be partially attributable to the fact that the available literature on this topic is limited and novel; all of the studies were published in the past five years and more than half of the included studies were published later than 2012.

The generalization of our findings is mainly hampered by the retrospective nature of the included studies, which were prone to selection or information bias and could lead to an overestimate of the effect [40]. Although we scrutinized carefully the available prospective trial studies on this issue, we found only a few, which were not initially designed to explore the proposed questions of our interest [37]. In addition, some of the included studies [7, 22, 26] were based on medical
records or insurance data that were not primarily designed to assess the effect of metformin use on prostate cancer, and the details on the dose, duration, variation over time in the process of treatment as well as full information on the potential confounders were incomplete; as a consequence, the dose-response relationship was not clarified in this meta-analysis.

In summary, based on the available observational studies, our analyses demonstrated metformin use was associated with 9% lower risk of prostate cancer, and with an 18% reduction in the BCR after the treatment of prostate cancer for metformin use. However, we failed to achieve a statistically significant association between metformin use and the all-cause mortality of patients with prostate cancer. Although any conclusions without a large-scale prospective randomized study should be cautious, considering the high prevalence of prostate cancer in Western countries and its rising incidence in the world [1], as long as the low cost and favorable toxicity of metformin, the applicability of metformin use as recommendation for prevention or treatment of prostate cancer may suit multiple populations, in people both with or without type 2 diabetes, and in both developed or developing countries. We expect further experimental investigations will be conducted to clarify the effect of metformin on prostate cancer. In fact, pioneers have already begun to act [41, 42].

Supporting Information

S1 Fig. Sensitivity analysis for the primary results. Sensitivity analyses for the effect of metformin use on (A) prostate cancer risk, (B) the BCR of prostate cancer and (C) the all-cause mortality of prostate cancer. The analysis was conducted by omitting each study in turn. Meta-analysis random-effects estimates were used. The two ends of the dotted lines represent the 95% CI.
doi:10.1371/journal.pone.0116327.s001 (TIF)

S2 Fig. Begger’s funnel plot of the publication bias for the primary results. Begger’s funnel plot of the publication bias for (A) the prostate cancer risk analysis, (B) the BCR analysis and (C) the all-cause mortality analysis. Each dot represents a separate study for the indicated association.
doi:10.1371/journal.pone.0116327.s002 (TIF)

S1 PRISMA Checklist. The PRISMA checklist for this meta-analysis.
doi:10.1371/journal.pone.0116327.s003 (DOC)

Author Contributions

Conceived and designed the experiments: XH HLY. Performed the experiments: HLY LY XSJ XJS JW HT. Analyzed the data: HLY XSG XH. Contributed reagents/materials/analysis tools: XH XSG. Wrote the paper: HLY.
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.

2. Papanas N, Maltezos E, Mikhailidis DP (2009) Metformin: diamonds are forever. Expert Opin Pharmacother 10: 2395–2397.

3. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314–1327.

4. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297–3302.

5. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576–3586.

6. Murtola TJ, Tammela TL, Lahtela J, Auvina A (2008) Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 168: 925–931.

7. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, et al. (2013) Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev.

8. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, et al. (2012) Lower risk of cancer in patients on metformin compared to those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35: 119–124.

9. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20: 1617–1622.

10. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, et al. (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63: 709–716.

11. Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337–344.

12. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76: 1240–1244.

13. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, et al. (2014) Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32: 43 e41–47.

14. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, et al. (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3: 1451–1461.

15. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, et al. (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17: 813–822.

16. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, et al. (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 8: e71583.

17. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2011 Mar 19.

18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

19. Dong JY, He K, Wang P, Qin LQ (2011) Dietary fiber intake and risk of breast cancer: a meta-analysis of prospective cohort studies. Am J Clin Nutr 94: 900–905.

20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.

21. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

22. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766–1777.
23. Ferrara A, Lewis JD, Quesenberry CP, Jr., Peng T, Strom BL, et al. (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34: 923–929.
24. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, et al. (2012) The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012: 413782.
25. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, et al. (2013) Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. J Clin Oncol 31: 3069–3075.
26. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, et al. (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965–1971.
27. He XX, Tu SM, Lee MH, Yeung SC (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22: 2640–2645.
28. Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, et al. (2013) Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 105: 1123–1131.
29. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, et al. (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35: 299–304.
30. Allott EH, Abern MR, Gerber L, Koto CJ, Aronson WJ, et al. (2013) Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis.
31. Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34: 616–621.
32. Zannella V, Dal Pra A, Muaddi H, McKee T, Stapleton S, et al. (2013) Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical cancer research: an official journal of the American Association for Cancer Research.
33. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, et al. (2014) Metformin Use and Prostate Cancer Risk. Eur Urol.
34. van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55: 654–665.
35. Qi H, Rhoads GG, Berlin JA, Marcella SW, Demissie K (2013) Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 15: 349–357.
36. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et al. (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glaecmaemia in Diabetes) clinical trials. Diabetesologia 53: 1838–1845.
37. Uchio EM, Aslan M, Wells CK, Calderone J, Conacro J (2010) Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 170: 1390–1395.
38. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Stresel RT, et al. (2014) Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol.